GWPH - GWファ―マシュ―ティカルズ (GW Pharmaceuticals Plc) GWファ―マシュ―ティカルズ

 GWPHのチャート


 GWPHの企業情報

symbol GWPH
会社名 GW Pharmaceuticals Plc (GWファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols) which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial Sativex Research and Development and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.   GWファ―マシュ―ティカルズは英国のバイオ医薬品会社。色々な疾病の治療薬として、独自のカンナビノイド製品発見、開発、商業化に従事。同社の主要医薬品「サティベックス」を多発性硬化症、がんの痛み、神経痛の痛みを緩和させる口腔粘膜スプレ―治療薬として研究、開発中。   GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.
本社所在地 Sovereign House Vision Park Chivers Way Histon Cambridge CB24 9BZ GBR
代表者氏名 Geoffrey W. Guy ジェフリーW.ガイ
代表者役職名 Executive Chairman of the Board 取締役会長
電話番号 +44 1223-26-6800
設立年月日 1998年
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 583人
url www.gwpharm.com
nasdaq_url https://www.nasdaq.com/symbol/gwph
adr_tso 26599036
EBITDA EBITDA(百万ドル) -219.66910
終値(lastsale) 146.07
時価総額(marketcap) 3885321188.52
時価総額 時価総額(百万ドル) 3959.721
売上高 売上高(百万ドル) 16.56232
企業価値(EV) 企業価値(EV)(百万ドル) 3512.80622
当期純利益 当期純利益(百万ドル) -250.08300
決算概要 決算概要 BRIEF: For the six months ended 31 March 2018 GW Pharmaceuticals PLC- ADR revenues increased from £3.7M to £8.1M. Net loss increased from £50M to £109.6M. Revenues reflect Europe (Excluding UK) segment increase of 60% to £1.6M Canada segment increase from £0K to £196K. Higher net loss reflects Net foreign exchange (loss)/gain increase from £7.8M (income) to £17.2M (expense) Selling/General/Admin.

 GWPHのテクニカル分析


 GWPHのニュース

   Top Analyst Upgrades and Downgrades: Crocs, Gap, GW Pharma, Lowe’s, Merck, Nio, Palo Alto, Phillips 66, Starbucks, Vital Farms and More  2020/08/25 13:06:25 24/7 Wall street
   GW Pharmaceuticals PLC (GWPH) Q2 2020 Earnings Call Transcript | AlphaStreet  2020/08/11 14:18:56 AlphaStreet
GW Pharmaceuticals PLC (NASDAQ: GWPH) Q2 2020 earnings conference call dated August 06, 2020
   The Week In Cannabis: FDA Approves Epidiolex, Brett Favre Joins The Industry, Stocks In Red  2020/08/07 20:30:38 Benzinga
In a week where markets were up, cannabis stocks were mostly declining. The week started off on a good note, with GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) and Greenwich Biosciences Inc. jointly announcing FDA approval for Epidiolex, an oral solution aimed to manage seizures related to tuberous sclerosis complex. The companies said the age range includes patients one year of age and older. Besides the new indication, EPIDIOLEX, which is plant-derived CBD medicine, can also help those suffering from seizures linked to Lennox-Gastaut and Dravet syndromes. Initially, the medicine is approved by the FDA for treating both syndromes in patients two years of age and older. Illinois adult-use cannabis sales remained strong in July, hitting around $61 million. That’s a monthly increase of roughly 28%. In Michigan, speculation mounted around new cannabis licenses. According to some reports, starting Nov. 1, businesses and individuals aspiring a recreational marijuana license in Michigan may no longer need to be a medical marijuana license holder.
   GW Pharma shares slide 12% after company swings to loss during pandemic  2020/08/07 15:24:43 MarketWatch
Shares of GW Pharmaceuticals PLC undefined slumped 12% Friday, after the company swung to a loss in the second quarter, hurt by the effect of the coronavirus…
   GW Pharmaceuticals plc Reports Second Quarter 2020 Financial Results and Operational Progress  2020/08/06 20:00:00 GlobeNewswire
- Total revenue increased 68 percent to $121.3 million - - Epidiolex approved in the U.S. for seizures associated with TSC, launch expected this month - -…
   The Week In Cannabis: FDA Approves Epidiolex, Brett Favre Joins The Industry, Stocks In Red  2020/08/07 20:30:38 Benzinga
In a week where markets were up, cannabis stocks were mostly declining. The week started off on a good note, with GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) and Greenwich Biosciences Inc. jointly announcing FDA approval for Epidiolex, an oral solution aimed to manage seizures related to tuberous sclerosis complex. The companies said the age range includes patients one year of age and older. Besides the new indication, EPIDIOLEX, which is plant-derived CBD medicine, can also help those suffering from seizures linked to Lennox-Gastaut and Dravet syndromes. Initially, the medicine is approved by the FDA for treating both syndromes in patients two years of age and older. Illinois adult-use cannabis sales remained strong in July, hitting around $61 million. That’s a monthly increase of roughly 28%. In Michigan, speculation mounted around new cannabis licenses. According to some reports, starting Nov. 1, businesses and individuals aspiring a recreational marijuana license in Michigan may no longer need to be a medical marijuana license holder.
   GW Pharma shares slide 12% after company swings to loss during pandemic  2020/08/07 15:24:43 MarketWatch
Shares of GW Pharmaceuticals PLC undefined slumped 12% Friday, after the company swung to a loss in the second quarter, hurt by the effect of the coronavirus…
   GW Pharmaceuticals plc Reports Second Quarter 2020 Financial Results and Operational Progress  2020/08/06 20:00:00 GlobeNewswire
- Total revenue increased 68 percent to $121.3 million - - Epidiolex approved in the U.S. for seizures associated with TSC, launch expected this month - -…
   GW Pharmaceuticals Q2 2020 Earnings Preview (NASDAQ:GWPH)  2020/08/05 17:28:38 Seeking Alpha
GW Pharmaceuticals (NASDAQ:GWPH) is scheduled to announce Q2 earnings results on Thursday, August 6th, after market close. The consensus EPS Estimate is -$
   FDA Approves CBD Meds From GW Pharmaceuticals To Treat Seizures  2020/08/03 17:56:35 Benzinga
GW Pharmaceuticals plc (NASDAQ: GWPH ) and Greenwich Biosciences Inc. jointly announced FDA approval for EPIDIOLEX , an oral solution aimed to manage seizures related to tuberous sclerosis complex. The companies said the age range includes patients one year of age and older. Besides the new indication, EPIDIOLEX, which is plant-derived CBD medicine, can also help those suffering from seizures linked to Lennox-Gastaut and Dravet syndromes. Initially, the medicine is approved by the FDA for treating both syndromes in patients … Full story available on Benzinga.com
   The Daily Biotech Pulse: Sanofi-GSK Land $2.1M Funding For Coronavirus Vaccine, D-Day For GW Pharma, FDA Nod For Roche  2020/07/31 07:45:00 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 30) Achieve Life Sciences Inc (NASDAQ: ACHV) Annexon Inc (NASDAQ: ANNX) (IPOed July …
   The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings  2020/07/26 13:54:59 Benzinga
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks. Although there were promising updates from some coronavirus vaccine makers, negative headlines plagued Novavax, Inc. (NASDAQ: NVAX ) and Moderna Inc (NASDAQ: MRNA ), sending their stocks lower by 4.7% and 23%, respectively, for the week. The week saw the listing of 4 biopharma companies on the Nasdaq, which raised a combined $772.9 million. Here are the key catalysts for the unfolding week. Conferences: Alzheimer's Association International Conference, or AAIC, to be held virtually: July 27-31 PDUFA Dates The FDA is set to rule on Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE ) NDA for UX007, its investigational drug for long-chain fatty acid oxidation disorders. (Friday) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) has a PDUFA action date, with the FDA due to announce its verdict on the company's sNDA for Epidiolex for the treatment of seizures associated with tuberous sclerosis complex.
   Top Analyst Upgrades and Downgrades: Apple, AT&T, CenturyLink, Fortinet, Gap, GW Pharma, Halliburton, Marvell, Schlumberger, Wells Fargo, Western Digital and More  2020/07/15 13:11:12 24/7 Wall street
   GW Pharmaceuticals stock slips after Stifel analyst backs off long-standing bullish view  2020/07/15 12:22:47 MarketWatch
Shares of GW Pharmaceuticals PLC undefined fell 0.4% in premarket trading, after Stifel Nicolaus analyst Paul Matteis downgraded the maker of the…
   Cannabis Stock Gainers And Losers From July 14, 2020  2020/07/14 21:11:53 Benzinga Feeds
Gainers BIOHARVEST SCIENCES INC (OTC: CNVCF) shares closed up 29.55% at $0.10 Intec Pharma (NASDAQ: NTEC ) shares closed up 13.83% at $0.30 Bloom Energy (NYSE: BE ) shares closed up 8.18% at $13.09 High Tide (OTC: HITIF ) shares closed up 6.91% at $0.12 Cipher Pharms Inc (OTC: CPHRF ) shares closed up 6.83% at $0.96 GW Pharmaceuticals (NASDAQ: GWPH ) shares closed up 5.56% … Full story available on Benzinga.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 GWファ―マシュ―ティカルズ GWPH GW Pharmaceuticals Plc)

 twitter  (公式ツイッターやCEOツイッターなど)